JP2023544724A5 - - Google Patents

Info

Publication number
JP2023544724A5
JP2023544724A5 JP2023519831A JP2023519831A JP2023544724A5 JP 2023544724 A5 JP2023544724 A5 JP 2023544724A5 JP 2023519831 A JP2023519831 A JP 2023519831A JP 2023519831 A JP2023519831 A JP 2023519831A JP 2023544724 A5 JP2023544724 A5 JP 2023544724A5
Authority
JP
Japan
Prior art keywords
unsubstituted
pharmaceutical composition
use according
substituted
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544724A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/077057 external-priority patent/WO2022069690A2/en
Publication of JP2023544724A publication Critical patent/JP2023544724A/ja
Publication of JP2023544724A5 publication Critical patent/JP2023544724A5/ja
Pending legal-status Critical Current

Links

JP2023519831A 2020-10-02 2021-10-01 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム Pending JP2023544724A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063086830P 2020-10-02 2020-10-02
US63/086,830 2020-10-02
US202063114769P 2020-11-17 2020-11-17
US63/114,769 2020-11-17
US202163241891P 2021-09-08 2021-09-08
US63/241,891 2021-09-08
PCT/EP2021/077057 WO2022069690A2 (en) 2020-10-02 2021-10-01 Methods for delivery of psychedelic medications by inhalation and systems for performing the methods

Publications (2)

Publication Number Publication Date
JP2023544724A JP2023544724A (ja) 2023-10-25
JP2023544724A5 true JP2023544724A5 (https=) 2024-07-29

Family

ID=78080292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519831A Pending JP2023544724A (ja) 2020-10-02 2021-10-01 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム

Country Status (7)

Country Link
US (1) US20230355583A1 (https=)
EP (1) EP4221682A2 (https=)
JP (1) JP2023544724A (https=)
KR (1) KR20230079351A (https=)
AU (1) AU2021354006A1 (https=)
CA (1) CA3194558A1 (https=)
WO (1) WO2022069690A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
EP4463440A1 (en) * 2022-01-14 2024-11-20 Cybin IRL Limited Tryptamine compositions and methods
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CA3246274A1 (en) * 2022-03-31 2023-10-05 Cybin Irl Limited METHODS OF ADMINISTRATING PSYCHEDELIC MEDICINES BY INHALATION AND SYSTEMS FOR IMPLEMENTING THESE METHODS
AU2023361184A1 (en) * 2022-10-13 2025-04-24 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
WO2024081962A2 (en) * 2022-10-14 2024-04-18 Invyxis, Inc. Acetal, ketal, and hemiaminal analogs of psilocin, processes for the preparation thereof, and methods of use
US12280216B2 (en) 2023-02-01 2025-04-22 Thomas E. Garrison Mixtures including nitrous oxide
US11980717B1 (en) * 2023-02-01 2024-05-14 Thomas E. Garrison Mixtures including nitrous oxide
WO2025010308A2 (en) * 2023-07-03 2025-01-09 Empathbio, Inc. Mdma enantiomer compositions and methods for modulating aggression response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7267121B2 (en) 2004-04-20 2007-09-11 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
CN102014995B (zh) * 2007-03-30 2015-05-13 菲利普莫里斯生产公司 用于输送药剂的装置和方法
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
FI4349407T3 (fi) * 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
RU199823U1 (ru) 2020-06-10 2020-09-21 Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий Устройство для лечения бронхолегочных заболеваний

Similar Documents

Publication Publication Date Title
JP2023544724A5 (https=)
JP2023544724A (ja) 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム
CN102264703B (zh) 作为β2肾上腺素受体促效剂的5-(2-{[6-(2,2-二氟-2-苯基乙氧基)己基]氨基}-1-羟乙基)-8-羟基喹啉-2(1H)-酮的甲磺酸盐
AU2022342266B2 (en) Combination drug therapies
JP2001513492A (ja) 生物活性巨大分子を含む水性エアゾール製剤及び該エアゾールの製造方法
JP2004523594A5 (https=)
CN1649588A (zh) 基于抗胆碱能药物及pde-iv抑制剂的新颖药物组合物
EP4499087A1 (en) Combination of nitrous oxide and 5-ht2a receptor agonists
KR20240013170A (ko) 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
JP2025510942A5 (https=)
TW200536533A (en) Organic compounds
WO2021230340A1 (ja) 新規吸入剤
TW201031408A (en) Novel methods
JP2025510944A5 (https=)
JP2005505560A (ja) 三環系5,6−ジヒドロ−9H−ピラゾロ(3,4−c)−1,2,4−トリアゾロ(4,3−アルファ)ピリジンを含む吸入組成物
KR20240134951A (ko) 트립타민 조성물 및 방법
TW200800141A (en) HFC solution formulations containing salbutamol hydrochloride or salbutamol citrate
EA012583B1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
US20210046258A1 (en) Method and apparatus for producing fine concentrated aerosol
US20250205198A1 (en) Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
TW200835490A (en) Novel substituted piperidyl-propane-thiols
AU2023331937A1 (en) Tryptamine compounds, compositions, and methods of use
US20230100890A1 (en) Use of combined inhalant cannabinoid therapy in the treatment of migraine
CN1642525A (zh) 无水化合物的hfa混悬剂
JP2025500344A (ja) 睡眠時無呼吸の治療のためのα2-アドレナリン受容体サブタイプC(アルファ-2C)アンタゴニストとノルエピネフリン再取込み阻害薬との組合せ